Eli Lilly & Co. (LLY)
Eli Lilly & Co. is a global pharmaceutical company founded in 1876, focused on developing innovative medicines in areas such as oncology, neuroscience, diabetes, and immunology. The company is known for its research-driven approach and has a strong portfolio of prescription drugs and biologics aimed at improving patient health worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 10, 2025 | $1.50 | 2025-08-15 | 2025-08-15 |
| June 10, 2025 | $1.50 | 2025-05-16 | 2025-05-16 |
| March 10, 2025 | $1.50 | 2025-02-14 | 2025-02-14 |
| December 10, 2024 | $1.30 | 2024-11-15 | 2024-11-15 |
| September 10, 2024 | $1.30 | 2024-08-15 | 2024-08-15 |
Dividends Summary
- Eli Lilly & Co. has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 27 days ago, on September 10, 2025
- The highest dividend payed out to investors during this period was $1.50 per share
- The average dividend paid during this period was $0.64 per share.
Company News
Trogenix, a biotech company founded by 4BIO Capital, raised £70 million in Series A financing to advance potentially curative cancer therapies, with a lead program targeting glioblastoma entering clinical trials in Q1 2026.
Two pharmaceutical companies, Novo Nordisk and Vertex Pharmaceuticals, present attractive investment opportunities despite recent market challenges, with strong financials, promising drug pipelines, and potential for future growth.
Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases.
Tandem Diabetes Care announced its t:slim X2 insulin pump is now compatible with Eli Lilly's Lyumjev ultra-rapid acting insulin in the United States, expanding insulin therapy options for people with type 1 and type 2 diabetes.
Novo Nordisk and Eli Lilly have both cut prices on their weight-loss drugs Wegovy and Zepbound, respectively, in an apparent price war to attract more customers.
